Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

John F. Tisdale, Francis J. Pierciey, Melissa Bonner, Alexis A. Thompson, Lakshmanan Krishnamurti, Markus Y. Mapara, Janet L. Kwiatkowski, Ilya Shestopalov, Jean Antoine Ribeil, Wenmei Huang, Mohammed Asmal, Julie Kanter, Mark C. Walters*

*Corresponding author for this work

Research output: Contribution to journalLetter

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Hematology

Cite this

Tisdale, J. F., Pierciey, F. J., Bonner, M., Thompson, A. A., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Shestopalov, I., Ribeil, J. A., Huang, W., Asmal, M., Kanter, J., & Walters, M. C. (Accepted/In press). Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. American Journal of Hematology. https://doi.org/10.1002/ajh.25867